US Pushes Back Small-Package Customs Rule Until After Midterms as Prescription-Drug Alarms Grow

CBP Quietly Moves the Date

The United States government has given American shoppers and patients a 90-day reprieve from a major customs overhaul that had been set to take effect twelve days before the midterm elections. US Customs and Border Protection said it is pushing the mandatory compliance date for a new mail-entry process for small international shipments from October 22 to January 20, 2027, according to Reuters, which reported the agency’s announcement on Wednesday.

The move means there will be no changes to international mail entry procedures until well after voters cast their ballots on November 3, in an election in which household affordability has emerged as a defining issue for control of Congress.

The rule in question targets the de minimis tariffs exemption, a longstanding provision that let shipments valued under $800 enter the United States with minimal requirements. The change would accelerate implementation of measures authorized by lawmakers as part of President Donald Trump’s spending and tax-cut bill, which are otherwise due to take full effect in July 2027.

Under the new process, electronic filing would be required for postal shipments subject to Section 201, 232 or 301 duties, or that fall under the jurisdiction of a partner government agency such as the Food and Drug Administration, along with a customs bond, Reuters reported. As the October 22 deadline approached, patient advocates and industry groups had warned that the data and bonding requirements could cause delays, refusals, or added costs for personal drug orders placed with pharmacies abroad.

“The 90-day extension provides importers, brokers, and logistics providers additional time to update their processes while helping avoid disruptions to certain international postal shipments destined for the United States,” CBP said in a statement posted on its website, according to USA Today, which reported the delay less than an hour before this article went to press.

Why Prescription Drugs Became the Flashpoint

The loudest warnings came from patients and pharmacies, not from trade lobbyists. The FDA officially bars individuals from importing foreign prescription drugs, but it exercises discretion in limited circumstances, Reuters noted. In practice, many Americans order medicines from other countries — often Canada, where prices can be sharply lower — and have relied for years on personal-use importation that passes through the mail system with little friction.

The Canadian International Pharmacy Association said most routine personal orders from licensed foreign pharmacies could have been disrupted by the new requirements, according to Reuters. USA Today’s framing was blunter: with the rule originally arriving on October 22, consumers were “one additional drug refill away from being cut off.”

Starting January 20, all international packages would have to go through a stricter entry process requiring more documentation and, for drugs, greater FDA scrutiny, USA Today reported. The change traces back to the broader dismantling of the de minimis rule, which the Trump administration suspended indefinitely last year for all low-value shipments.

For a 70-year-old retiree in Florida who orders a three-month supply of a blood-pressure drug from a licensed Canadian pharmacy at a fraction of the US price, the difference between a package that sails through the mail stream and one that sits in a bonded warehouse awaiting electronic filings is not abstract. It is the difference between an uninterrupted prescription and a gap in treatment.

A 90-Year-Old Rule Meets the E-Commerce Age

The de minimis provision — rooted in Section 321 of the Tariff Act — for nearly a century let packages worth $800 or less enter the United States free of duty, with no formal customs entry and no broker required. For most of its life it was an obscure trade-law curiosity. Then e-commerce happened.

At its peak, Customs and Border Protection processed more than a billion de minimis shipments a year, the vast majority originating in China. By 2024, low-value packages accounted for a reported 92 percent of the total volume of US imports, with around 600,000 parcels arriving daily from platforms like Shein and Temu alone.

The Trump administration dismantled the exemption in stages. First, an executive order eliminated it for shipments from China and Hong Kong, effective May 2, 2025; those packages became subject to the applicable tariff rate or a flat postal duty initially set at $100 per item, rising later in the year. In July 2025, Trump signed a follow-on executive order extending the change to all other countries, effective August 29, 2025. Congress then voted to eliminate the exemption outright for commercial shipments by mid-2027.

The stated rationale was framed around enforcement: the administration argued the exemption had become a channel for precursor chemicals, counterfeit goods and fentanyl to enter the country with minimal scrutiny. CBP’s own guidance echoed that concern. The economic effect, however, was a shock to the small-parcel supply chain.

In the final days before the rule ended, Temu added import charges of 130 to 150 percent on goods it still shipped from China — in many cases exceeding the price of the goods themselves — while Shein raised US prices, according to trade-press reporting citing NPR and CNN price checks. A swimsuit set on Shein that cost $4.39 rose to $8.39 in a single day, CNN found.

What the Rollback Has Already Cost the Mail System

The numbers that followed were dramatic. CBP has reported collecting over a billion dollars in duties on more than 246 million low-value shipments in the months after the initial rollback, according to a summary compiled in a Congressional Research Service brief — revenue that under the old regime would never have reached the Treasury at all.

The Universal Postal Union, meanwhile, published a report finding that by September 2025, one month after the US removed the de minimis rule, the total weight of small packages entering the United States had fallen by 70.3 percent compared with the same period a year earlier. Postal operators in Germany, Japan, Switzerland and other countries halted shipments to the US altogether, unable to navigate the new paperwork.

Between September 2025 and May 2026, only 67 percent of postal shipments went through informal or formal clearance, according to a CBP proposal document — evidence that the system was struggling to absorb the new compliance burden. A separate proposed rule would create a new “Informal Mail Entry” category with electronic filing requirements, sender data and a basic bond carrying a $1,000 minimum per violation — a proposal CBP itself classifies as “economically significant,” estimating roughly $9.3 billion in net costs to the economy between 2026 and 2035.

The courts have so far sided with the administration: on August 13, 2026, a three-judge panel of the Court of International Trade rejected a challenge from auto-parts importer Detroit Axle, ruling that withdrawing a duty-free exemption is legally distinct from imposing a new tariff — so the de minimis suspension stands even after the Supreme Court struck down separate emergency-power tariffs in February 2026.

Analysis: Why It Matters

The delay is not a reversal of policy — CBP has stressed that the underlying rule remains intact and the 90-day window is about giving importers, brokers and logistics providers time to update their processes. But the calendar is doing the talking. A deadline of October 22, twelve days before a midterm election in which control of Congress is up for grabs, would have landed precisely on the nerve of the electorate: prices. The new date of January 20, 2027 — inauguration-adjacent, safely past the voting — moves the pain past the ballot box.

Affordability is not a theoretical talking point this cycle. Reuters’ own domestic news summary this week notes that toy prices have surged 6.6 percent over the past year, squeezed by the double impact of tariffs and high energy costs, and that consumer-goods price studies from the Federal Reserve Bank of New York attribute roughly 2.9 percentage points of goods-price inflation to tariffs. When the administration’s own tariff program is pushing holiday shopping costs higher, the last thing its party wants twelve days before Election Day is a customs paperwork regime that might interrupt a grandmother’s heart medication.

The patient angle matters because it exposes the structural tension at the heart of the de minimis debate. The original sin of the exemption was opacity: packages flowing invisibly through the system made enforcement against fentanyl precursors and counterfeits nearly impossible. But that same invisibility was what let a pensioner import an affordable prescription from Toronto, or a small business in Ohio receive a sample shipment from Shenzhen, without hiring a customs broker. Every layer of scrutiny added to block the bad actors raises the cost floor for the ordinary ones.

Watch, too, for what the extension signals about industry readiness. When CBP concedes that importers and postal operators need another 90 days to update processes — a full year after the first de minimis suspension began — it confirms how difficult the transition has been. The 67-percent clearance figure is the quiet indictment: nearly a third of postal shipments still were not being properly cleared almost nine months after the change. That is not a teething problem; it is a structural mismatch between the ambition of the policy and the capacity of the infrastructure.

Finally, there is the international dimension. The de minimis rollback was arguably Washington’s most consequential trade instrument of 2025 — one that quietly rebuilt the economics of cross-border shopping, forced postal operators in allied countries to suspend services, and moved more than a billion dollars into Treasury coffers. That it now has to be softened on a 90-day leash because the plumbing cannot keep up is a reminder that tariffs are not only taxes on foreign producers. They are, in practice, paperwork on Americans.

What to Watch Next

1. The January 20, 2027 deadline. CBP says there will be no changes to international mail entry procedures before then. Expect another round of lobbying from patient groups and pharmacy associations if the electronic-filing and bonding requirements remain unchanged.
2. Whether the formal de minimis repeal accelerates. Congress has already voted to end the exemption outright for commercial shipments by July 2027; the interim January deadline is the bridge. Watch for attempts to carve out explicit protections for personal drug orders.
3. Postal-operator readiness. Germany, Japan and Switzerland suspended US-bound shipments once; if carriers conclude they cannot handle the new entry process, another wave of suspensions could follow — this time after the election.
4. Affordability as a midterm issue. The delay was plainly timed around November 3. Both parties will campaign on household costs; the de minimis saga is now part of that fight.
5. The courts. The Detroit Axle ruling upheld the suspension, but litigation over the broader tariff regime — including the $130 billion in refunds now being processed after the Supreme Court’s February ruling — continues. The legal boundary between withdrawing an exemption and imposing a tariff will be tested again.

Sources

• Reuters: “US delays small imports rule that raised alarm over prescription drug costs” (Kamal Choudhury, Oct 15, 2026)
• USA Today: “Americans’ prescription drug orders from overseas are safe – for now” (Oct 16, 2026)
• The Diplomatic Insight: “How Washington’s De Minimis Rollback Is Reshaping Global Trade”
• Global Trade Magazine: “De Minimis Tariff Exemption Ends: How Shein and Temu Prices Doubled for U.S. Shoppers”